Needham & Company Reiterates a 'Buy' on Alnylam Pharma (ALNY); Phase 2b Trial Misses, But Shares Still Undervalued

Go back to Needham & Company Reiterates a 'Buy' on Alnylam Pharma (ALNY); Phase 2b Trial Misses, But Shares Still Undervalued